Strategic collaboration Potential for partnerships with CROs like Clinical Accelerator to run Phase II mechanistic studies in STEMI and thrombotic indications, enabling joint development and faster validation of TSI's novel proUK-based therapy.

Clinical pipeline Focus on a first-in-class clot-dissolving therapy with a novel mechanism of action, targeting stroke and thrombotic diseases, presenting a differentiated value proposition for downstream clinical adoption and investment.

Financing runway Current funding of around $7.5M alongside sub-$1M revenue signals a need for additional grant, partner, or non-dilutive funding to accelerate R&D and clinical milestones, presenting an entry point for investor and grant outreach.

Resource-limited selling Small team size (2-10 employees) suggests high-touch, relationship-driven sales motions and the opportunity to position as a specialized, high-value supplier of research tools, services, or milestone-based collaborations.

Tech-enabled reach Utilize existing digital presence and tech stack (Wix, WordPress, cloud, analytics) to deploy targeted outreach and patient/clinician education campaigns, boosting visibility among biotech partners, CROs, and academic collaborators.